

Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study

OPEN ACCESS

Edited by:

Gerald J. Maarman, Stellenbosch University, South Africa

Reviewed by:

Yuli Huang, Southern Medical University, China Qianyun Guo, Capital Medical University, China

*Correspondence:

Tingting Tang tangtingting@hust.edu.cn Xiang Cheng nathancx@hust.edu.cn

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Cardiovascular Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 21 December 2021 Accepted: 16 February 2022 Published: 22 April 2022

Citation:

Huang M, Laina-Nicaise L-D, Zha L, Tang T and Cheng X (2022) Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study. Front. Endocrinol. 13:840579. doi: 10.3389/fendo.2022.840579 Mingkai Huang^{1,2†}, Loum-Davadi Laina-Nicaise^{1,2†}, Lingfeng Zha^{1,2†}, Tingting Tang^{1,2*} and Xiang Cheng^{1,2*}

¹ Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ² Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Objective: We aimed to evaluate the causal effect of type 2 diabetes mellitus (T2DM) and glycemic traits on the risk of a wide range of cardiovascular diseases (CVDs) and lipid traits using Mendelian randomization (MR).

Methods: Genetic variants associated with T2DM, fasting glucose, fasting insulin, and hemoglobin A1c were selected as instrumental variables to perform both univariable and multivariable MR analyses.

Results: In univariable MR, genetically predicted T2DM was associated with higher odds of peripheral artery disease (pooled odds ratio (OR) =1.207, 95% CI: 1.162-1.254), myocardial infarction (OR =1.132, 95% CI: 1.104-1.160), ischemic heart disease (OR =1.129, 95% CI: 1.105-1.154), heart failure (OR =1.050, 95% CI: 1.029-1.072), stroke (OR =1.087, 95% CI: 1.068-1.107), ischemic stroke (OR =1.080, 95% CI: 1.059-1.102), essential hypertension (OR =1.013, 95% CI: 1.010-1.015), coronary atherosclerosis (OR =1.005, 95% CI: 1.004-1.007), and major coronary heart disease event (OR =1.003, 95% CI: 1.002-1.004). Additionally, T2DM was causally related to lower levels of high-density lipoprotein cholesterol (OR =0.965, 95% CI: 0.958-0.973) and apolipoprotein A (OR =0.982, 95% CI: 0.977-0.987) but a higher level of triglycerides (OR =1.060, 95% CI: 1.036-1.084). Moreover, causal effect of glycemic traits on CVDs and lipid traits were also observed. Finally, most results of univariable MR were supported by multivariable MR.

Conclusion: We provided evidence for the causal effects of T2DM and glycemic traits on the risk of CVDs and dyslipidemia. Further investigations to elucidate the underlying mechanisms are warranted.

Keywords: Mendelian randomization, diabetes, glycemic traits, cardiovascular disease, lipid

INTRODUCTION

Evidence from mounting prospective cohort studies has shown that type 2 diabetes mellitus (T2DM) is an independent risk factor of various cardiovascular diseases (CVDs) including coronary heart disease, heart failure (HF), stroke, peripheral artery disease (PAD) and so on (1-3). However, the causal effect of T2DM on CVDs could be confused by body mass index, age, sex, ethnicity, etc. in observational studies. Abnormal glycemic traits in the non-diabetic range, including fasting glucose (FG), fasting insulin (FI), and hemoglobin A1c (HbA_{1c}), were reported to be associated with CVDs (2-5). However, there are still conflict findings (6-11). Thus, the association remains uncertain. Patients with T2DM or abnormal glycemic traits were observed to predispose to the development of dyslipidemia such as increased low-density lipoprotein cholesterol (LDL-C), increased triglyceride, and decreased high-density lipoprotein cholesterol (HDL-C) (12). However, whether T2DM or abnormal glycemic trait is a cause or consequence of dyslipidemia is uncertain.

Mendelian randomization (MR) is an approach that relies on genetic variants that are considered to be allocated randomly at birth and is less subject to many confounders than observational studies (13). A previous MR study has investigated the relationship between T2DM and CVDs in a single cohort and revealed causal effects of T2DM on a range of CVDs (14). In our MR study, we pooled the estimates from two independent cohorts to ensure the robustness of the causal effects of T2DM on CVDs. Besides, we took three glycemic traits (FG, FI and HbA_{1c}) closely related to T2DM into consideration and conducted multivariable analyses to avoid bias of confounders brought by these traits. We further explored whether the causal effect of T2DM on CVDs was mediated by dyslipidemia using mediation analysis. Additionally, we evaluated whether genetically predicted T2DM or abnormal glycemic traits are causally associated with lipid traits.

MATERIALS AND METHODS

MR and Genome-Wide Association Studies (GWAS) Summary Data

MR is a genetic instrumental variable (IV)-based approach that utilizes single nucleotide polymorphisms (SNPs) as IVs to clarify the causal association between exposure and outcome. In this study, two-sample MR was used. Our MR analysis was based on three basic assumptions: (1) the IVs were robustly associated with the exposures (T2DM and glycemic traits); (2) the IVs affected the outcomes (CVDs and lipid traits) merely by their effect on exposures without any other causal pathways, which is also called no pleiotropic effect from the exposures; and (3) the IVs were not associated with any confounders which are present in the relation between the exposures and outcomes. To assure the reliability of the causal link between the exposures and outcomes should be violated (**Figure 1**).

The summary-level data were obtained from the OpenGWAS database developed by the MRC Integrative Epidemiology Unit (IEU) (https://gwasmrcieu.ac.uk/). Most of the datasets were publicly available and could be obtained by accessing application programming interfaces through convenient packages in R and Python (15, 16). Details on the phenotypes and consortiums are available in **Supplementary Table 1**.

IVs for Exposures

We obtained the genetic instruments for T2DM from a metaanalysis of GWASs that included 74124 cases and 824006 controls from the DIAbetes Genetics Replication And Metaanalysis (DIAGRAM) consortium, which was derived from 32 GWASs conducted in populations of European ancestry (17). For the glycemic traits, the IVs for FG and FI were constructed from a meta-analysis of GWASs, which included 52 studies comprising up to approximately 133010 nondiabetic individuals from MAGIC (Meta-Analysis of Glucose and Insulin related traits Consortium) (18). The IVs for HbA_{1c} were obtained from a meta-analysis of 82 cohorts that included up to 88355 European participants (19). All SNPs with a p value $< 5 \times 10^{-8}$ were considered significant variants associated with phenotypes and included. We excluded SNPs with $r^2 < 0.001$ using linkage disequilibrium analysis. To avoid "weak instrument" bias, the F-statistic was calculated according to the formula $F = \frac{R^2(n-k-1)}{k(1-R^2)}$, where n, k, and R^2 represent the sample size, the number of SNPs, and the proportion of variance explained by the instrumental variants, respectively (20, 21). An F-statistic value > 10 was regarded as strong enough to avoid weak instrument bias (22). Finally, 286, 35, 18, and 38 SNPs served as IVs for T2DM, FG, FI, and HbA_{1c}, respectively (Supplementary Table 2).

GWAS Summary Data for CVDs

A broad spectrum of CVDs were included in our study. Summary statistics were extracted from the Coronary Artery Disease Genome-wide Replication and Meta-analysis (CARDIoGRAM) plus the Coronary Artery Disease (C4D) Genetics (CARDIoGRAMplusC4D) for myocardial infarction (MI) and ischemic heart disease (IHD) (23); from the UKB for coronary atherosclerosis (CA), major coronary heart disease event (MCHDE), essential hypertension (HT), intracerebral hemorrhage and cardiovascular mortality (CM) (24); from the MEGASTROKE Consortium for stroke and ischemic stroke (IS) (25); from the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) for HF (26); from the BioBank Japan (BBJ) for PAD (27); and from a meta-analysis including 6 studies (The Nord-Trøndelag Health Study (HUNT),

Abbreviations: T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease; FG, fasting glucose; FI, fasting insulin; HbA_{1c} , hemoglobin A1c; MR, Mendelian randomization; GWAS, genome-wide association study; IV, instrumental variable; SNP, single nucleotide polymorphism; MI, myocardial infarction; IHD, ischemic heart disease; CA, coronary atherosclerosis; MCHDE, major coronary heart disease event; HT, essential hypertension; CM, cardiovascular mortality; IS, ischemic stroke; HF, heart failure; PAD, peripheral artery disease; AF, atrial fibrillation and fluttering; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein A; ApoB, apolipoprotein B; Lp(a), lipoprotein(a); IVW, inverse variance-weighted; MVMR, multivariable MR.



deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, UKB, and the AFGen Consortium) for atrial fibrillation and fluttering (AF) (28).

To ensure the homogeneity of the study population and the reliabilities of the results, each CVD was derived from two independent large-scale cohorts. Therefore, summary-level data of each CVD were also extracted from the FinnGen consortium (study page: https://www.finngen.fi/en/; release 5: https://r5. finngen.fi/). According to the first occurrence, all CVDs were defined by the International Classification of Diseases (ICD)-10. The definition of each CVD is shown in **Supplementary Table 3**.

GWAS Summary Data for Lipid Traits

We explored the following lipid traits measured in the UKB (20): HDL-C, LDL-C, triglycerides, apolipoprotein A (apoA), apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)]. In addition, HDL-C, LDL-C, and triglycerides were explored again, utilizing the data from the Global Lipids Genetics Consortium (GLGC) to strengthen the credibility of the causal effects (29). We failed to reconduct analyses for the remaining three lipid traits due to the lack of data.

Statistical Analyses

For the primary analyses, the univariable inverse varianceweighted (IVW) method was used to investigate the effects of different exposures on outcomes (30). Using the Wald ratio estimates of each SNP, the IVW method combines them into one cumulative causal estimate. Since the results of the IVW method could be affected by undetectable invalid IV bias or potentially unbalanced pleiotropy, different sensitivity analyses were performed to detect the robustness and validity of the MR results. First, the MR–Egger method was used to confirm the consistency of MR results and explore the horizontal pleiotropy effect through the intercept (31). Second, the heterogeneity of IVW and MR–Egger was calculated (32). A fixed-effects model was adopted to assess the IVW estimates when there was no significant heterogeneity; otherwise, a random-effects model was used. Third, we applied the MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) method to recognize outlying SNPs, which might cause horizontal pleiotropy effects, and examine whether the causal effect would change after removing these outliers (33). Fourth, the weighted median, simple mode, and weighted mode were also employed to test the potential horizontal pleiotropy (34). Except for the analyses of apoA, apoB, and Lp(a), estimates of the causal effect from two independent cohorts were pooled using fixed-effects metaanalysis. It is also important to further evaluate whether the risk of CVDs in T2DM was mediated by dyslipidemia. Therefore, two-step MR was conducted to calculate the mediation effects of lipid traits in the relationship between T2DM and risk of CVDs (35).

For the complementary analyses, multivariable MR (MVMR) analysis was conducted using the IVW method, which incorporates different phenotypes as a single exposure into the MR analysis. In this study, since the relationship between T2DM and three glycemic traits was considered, we fitted a model with T2DM, FG, FI, and HbA_{1c} to detect which phenotypes appeared to be significantly associated with the risk of CVDs or abnormal lipid traits.

All MR analyses were performed using R (version 4.1.1). In the univariable MR step, estimates were obtained with the "TwoSampleMR" package, recognizing outliers with the "MR-PRESSO" package. The MVMR was conducted with the "MendelianRandomization" package. MR results were reported as odd ratios (ORs) with 95% confidence intervals (CIs) per standard deviation or odds of objectively measured continuous or dichotomous variables. For the primary analyses, since we included analyses of 18 outcomes, a Bonferroni-corrected p value less than 0.05 divided by 18 (that is, 0.0028) was regarded as a significant causal association to adjust for multiple testing. A pvalue between 0.05 and 0.0028 was considered suggestive of a potential association.

RESULTS

Primary Analyses

Univariable MR was conducted and 286, 35, 18, and 38 SNPs associated with T2DM, FG, FI, and HbA_{1c}, respectively, were selected as IVs. A flow chart of the study was presented in **Supplementary Figure 1**. An overview of the main results of the primary analyses was shown in **Figure 2**.

Causal Association of T2DM With CVDs and Lipid Traits

Genetically predicted T2DM was significantly associated with (ordered from largest estimate decreasing): PAD (OR = 1.207, 95% CI: 1.162-1.254, $p = 4.01 \times 10^{-22}$), MI (OR=1.132, 95% CI: 1.104-1.160, $p = 3.87 \times 10^{-22}$), IHD (OR = 1.129, 95% CI: 1.105-1.154, $p = 1.51 \times 10^{-28}$), stroke (OR = 1.087, 95% CI: 1.068-1.107, $p = 1.27 \times 10^{-19}$), IS (OR = 1.080, 95% CI: 1.059-1.102, $p = 1.40 \times 10^{-3}$), HF (OR = 1.050, 95% CI: 1.029-1.072, $p = 4.05 \times 10^{-6}$), HT (OR = 1.013, 95% CI: 1.010-1.015, $p = 6.28 \times 10^{-25}$), CA (OR = 1.005, 95% CI: 1.002-1.004, $p = 2.74 \times 10^{-11}$), and CM (OR = 1.001, 95% CI: 1.000-1.001, $p = 9.83 \times 10^{-6}$). We also found T2DM was causally related to lower levels of HDL-C (OR = 0.965, 95% CI: 0.958-0.973, $p = 2.13 \times 10^{-18}$) and apoA (OR = 0.982, 95% CI: 0.977-0.987, $p = 1.63 \times 10^{-11}$) but a higher level of triglycerides (OR = 1.060, 95% CI: 1.036-1.084, $p = 6.76 \times 10^{-7}$) (**Figure 3**).

Causal Association of Glycemic Traits With CVDs and Lipid Traits

Genetically predicted FG was significantly associated with PAD (OR = 1.911, 95% CI: 1.309-2.790, $p = 7.89 \times 10^{-4}$) and CA (OR = 1.014, 95% CI: 1.005-1.023, $p = 2.64 \times 10^{-3}$). Additionally, a potential increased risk was observed for IHD (OR =1.187, 95%

CI: 1.031-1.365, *p* value = 0.017), MCHDE (OR =1.008, 95% CI: 1.001-1.015, *p* value = 0.017), and CM (OR = 1.003, 95% CI: 1.001-1.005, $p = 3.61 \times 10^{-3}$) (**Figure 4**).

Genetically predicted FI was suggested to be positively corelated with PAD (OR = 2.804, 95% CI: 1.604-4.902, p = 2.97 × 10_4), IHD (OR = 2.020, 95% CI: 1.374-2.972, p = $3.53 \times 10_4$), MI (OR = 2.009, 95% CI: 1.317-3.064, $p = 1.20 \times 10^{-3}$) and HT (OR = 1.098, 95% CI: 1.054-1.144, $p = 8.31 \times 10^{-6}$) but negatively associated with HDL-C (OR = 0.644, 95% CI: 0.549-0.755, $p = 6.56 \times 10^{-8}$) and apoA (OR = 0.790, 95% CI: 0.713-0.874, $p = 5.37 \times 10^{-6}$). An indistinct relation to HF (OR = 1.442, 95% CI: 1.052-1.978, p = 0.023), stroke (OR = 1.421, 95% CI: 1.060-1.905, p = 0.019), IS (OR =1.480, 95% CI: 1.111-1.970, p = 0.007), CA (OR = 1.034, 95% CI: 1.006-1.064, p = 0.019), MCHDE (OR = 1.021, 95% CI: 1.001-1.042, p = 0.036) and lower level of Lp(a) (OR = 0.873, 95% CI: 0.780-0.978, p = 0.019) was also found (**Figure 5**).

Genetically predicted HbA_{1c} was significantly associated with CA (OR = 1.019, 95% CI: 1.008-1.031, $p = 6.58 \times 10^{-4}$) and an increased level of LDL-C (OR =1.205, 95% CI: 1.157-1.256, $p = 2.81 \times 10^{-19}$). A suggestive causal effect was also observed for IHD (OR =1.277, 95% CI: 1.075-1.516, p = 0.005) and MI (OR =1.220, 95% CI: 1.002-1.484, p = 0.047), and increased level of apoB (OR =1.056, 95% CI: 1.011-1.104, p = 0.015) (**Figure 6**).

Robustness of the Primary Analyses

In the univariable MR analysis, we observed significant heterogeneities in some estimates. We adopted a random-effects model to adjust the IVW estimates, as mentioned in the Methods section. The MR-Egger intercepts were mostly insignificantly larger or less than zero, eliminating part of the horizontal pleiotropy. Using the MR-PRESSO method, several outliers were identified during the analysis, and in most cases, the results



Outcomes	вета	Forrest Plot/ Udd Ratios (9	570 CI)	P value
Diseases				
Myocardial infarction		_		
CARDIoGRAMplusC4D	0.118		1.126 (1.092-1.161)	5.27E-14
FinnGen	0.134	→ →	1.143 (1.095-1.193)	1.02E-09
Pooled	0.124		1.132 (1.104-1.160)	3.87E-22
Heart failure				
HERMES	0.059	H H -1	1.061 (1.035-1.088)	3.38E-06
FinnGen	0.026	⊢−∎−−≀	1.026 (0.988-1.065)	0.178
Pooled	0.049	H H -1	1.050 (1.029-1.072)	4.05E-06
Ischemic heart disease				
CARDIoGRAMplusC4D	0.128	⊢ _ →	1.137 (1.105-1.170)	4.01E-18
FinnGen	0.114	⊢ ∎ →	1.120 (1.085-1.157)	4.32E-12
Pooled	0.122	⊢ ∎ →	1.129 (1.105-1.154)	1.51E-28
Coronary atherosclerosis			/	
UKB	0.005		1.005 (1.004-1.007)	1.89E-15
EinnGen	0.118	⊢ ∎	1 126 (1 085-1 168)	3.87E-10
Pooled	0.005	-	1 005 (1 004-1 007)	3.28E-16
Perinheral artery disease	0.005		1.003 (1.004 1.007)	0.201 10
	0.105		1 215 (1 145 1 200)	0.265 11
DDJ	0.193		1.213 (1.143-1.289)	5.30E-11 6.61E 12
Ported	0.100		1.201 (1.143-1.203)	0.01E-13
	0.100		1.207 (1.162-1.254)	4.01E-22
Essential hypertension	0.010	-	1 010 /1 010 1 01 *	1 545 00
UKB	0.012	-	1.012 (1.010-1.014)	1.54E-22
FinnGen	0.122	-	1.130 (1.095-1.166)	3.17E-14
Pooled	0.012	-	1.013 (1.010-1.015)	6.28E-25
Major coronary heart disease event				
UKB	0.003	-	1.003 (1.002-1.004)	6.92E-11
FinnGen	0.103	⊢ ∎→	1.109 (1.067-1.152)	1.11E-07
Pooled	0.003	-	1.003 (1.002-1.004)	2.74E-11
Stroke				
MEGASTROKE	0.074	⊢∎ 1	1.077 (1.052-1.102)	2.16E-10
FinnGen	0.099	⊢ ∎ 1	1.104 (1.071-1.137)	6.63E-11
Pooled	0.083	⊢∎⊣	1.087 (1.068-1.107)	1.27E-19
lschemic stroke				
MEGASTROKE	0.084	⊢∎ →	1.087 (1.061-1.114)	1.06E-11
FinnGen	0.063	► ■ →	1.065 (1.028-1.103)	4.88E-04
Pooled	0.077	⊢∎⊣	1.080 (1.059-1.102)	3.47E-14
Intracranial haemorrhage			(2.000 2.202)	
LIKR	-8 54F-04		0 999 (0 998-1 000)	1 72E-01
FinnGen	0.078		1.081 (1.016-1.140)	1 33E_02
Pooled	8.23E 04		0.000 (0.008 1.000)	1.86E_01
Atrial fibrillation and fluttoring	-0.23E-04		0.555 (0.550-1.000)	1.00E-01
Auta institution and futtering	0.019		1 010 (0 005 1 0 40)	0.117
iviuiti-conorts	0.018		1.018 (0.995-1.042)	0.117
FinnGen	0.015		1.015 (0.972-1.060)	0.505
Pooled	0.017	1- B -1	1.018 (0.997-1.038)	0.088
Cardiovascular mortality				
UKB	0.001	•	1.001 (1.000-1.001)	1.07E-05
FinnGen	0.056	► • • • • • • • • • • • • • • • • • • •	1.058 (1.013-1.104)	0.011
Pooled	0.001		1.001 (1.000-1.001)	9.83E-06
Lipid traits				
HDL cholesterol				
UKB	-0.033		0.967 (0.960-0.975)	6.62E-16
GLGC	-0.075 🔫 🛶		0.928 (0.894-0.962)	6.06E-05
Pooled	-0.035	1	0.965 (0.958-0.973)	2.13E-18
LDL cholesterol				
LIKB	-0.025		0 975 (0 957-0 994)	0.010
GLCC	0.017		1 017 (0 995-1 040)	0.134
Pooled	-0.007		0.003 (0.078-1.040)	0.317
Triglycerides	-0.001		0.000 (0.070-1.007)	0.017
	0.050		1.060 (1.022, 1.020)	1615 05
UKB	0.059		1.000 (1.033-1.088)	T.01E-02
GLGC	0.056		1.058 (1.009-1.109)	0.020
Pooled	0.058		1.060 (1.036-1.084)	6.76E-07
Apolipoprotein A				
UKB	-0.018		0.982 (0.977-0.987)	1.63E-11
Apolipoprotein B				
UKB	-0.003	•	0.997 (0.991-1.004)	0.377
Lipoprotein A				
UKB	0.001	•	0.997 (0.991-1.004)	0.961

FIGURE 3 | The association between type 2 diabetes mellitus and outcomes.

remained consistent with the original ones after removing these outliers. In addition, estimates using MR–Egger, weighted median, simple mode, and weighted mode were also calculated, and the results suggested relatively high robustness (**Supplementary Tables 4–7**).

Mediation Analyses

We performed mediation analyses using two-step MR to clarify whether the causal effect of T2DM on the risk of CVDs was

mediated by dyslipidemia. HDL-C, triglycerides and apoA were chosen as potential mediators since they showed a significant association with T2DM in the primary analyses. We found HDL-C explained a small part of the casual effects of T2DM on the risk of MI, CA, PAD, and HT, and the mediation proportions were 7.4%, 12.8%, 10.6%, and 5.9%, respectively (**Supplementary Table 8**). Triglycerides and apoA were also mediators of the causal association between T2DM and several types of CVDs (**Supplementary Tables 9, 10**).

Outcomes	Beta	Forrest Plot/ Odd Ratios	(95% CI)	P value
Diseases				
Myocardial infarction				
CARDIoGRAMplusC4D	0.214		1.239 (1.018-1.508)	0.032
FinnGen	0.170	⊢ ∎ →	1.186 (0.870-1.617)	0.281
Pooled	0.202	·∎	1.224 (1.037-1.444)	0.017
Heart failure			, , ,	
HERMES	0.170		1.186 (0.999-1.407)	0.051
FinnGen	-0.257		0.774 (0.585-1.023)	0.072
Pooled	0.054		1.056 (0.912-1.222)	0.468
Ischemic heart disease			,	
CARDIoGRAMplusC4D	0.241	·	1 272 (1 054-1 536)	0.012
FinnGen	0.085		1.088 (0.882-1.343)	0.429
Pooled	0.171		1.187 (1.031-1.365)	0.017
Coronany atherosclerosis	0.171		1.107 (1.031-1.303)	0.017
	0.014	-	1.014 (1.005 1.022)	2 155 02
FinaCon	0.014		1.014 (1.000-1.023)	0.154
Finngen	0.014		1.176 (0.940-1.477)	0.154
Poolea	0.014	-	1.014 (1.005-1.023)	2.64E-03
reripheral artery disease	0 701		2 206 (1 271 2 267)	4.005.00
BBJ	0.791		2.206 (1.271-3.827)	4.90E-03
FinnGen	0.520		1.682 (1.000-2.831)	0.050
Pooled	0.648		1.911 (1.309-2.790)	7.89E-04
Essential hypertension				
UKB	0.005	•	1.005 (0.988-1.023)	0.547
FinnGen	-0.172 H		0.842 (0.675-1.050)	0.127
Pooled	0.004	•	1.004 (0.987-1.022)	0.630
Major coronary heart disease event				
UKB	0.008		1.008 (1.001-1.015)	0.017
FinnGen	-0.005	·	0.995 (0.765-1.293)	0.969
Pooled	0.008	-	1.008 (1.001-1.015)	0.017
Stroke				
MEGASTROKE	0 172	· · · · · · · · · · · · · · · · · · ·	1 187 (0 970-1 453)	0.095
EinnGen	0.112		1 119 (0 880-1 422)	0.359
Pooled	0.147		1 159 (0 993-1 352)	0.062
Ischemic stroke	0.141	_	1.100 (0.000 1.002)	0.002
MEGASTROKE	0.206		1 228 (0 002 1 520)	0.058
EinnGon	0.087		1.001 (0.816 1.450)	0.557
Pringen	0.007		1.091 (0.010-1.409)	0.001
Pooled	0.104		1.170 (0.995-1.599)	0.001
Intracramar naemorrnage	1 455 00		0.000 (0.007 1.000)	0.1.40
UKB	-1.45E-03		0.999 (0.997 - 1.000)	0.140
FinnGen	1.131		3.099 (1.028-9.340)	0.045
Pooled	-1.45E-03		0.999 (0.997-1.000)	0.140
Atrial fibrillation and fluttering				
Multi-cohorts	-0.052	·-■	0.950 (0.837-1.077)	0.420
FinnGen	-0.256		0.774 (0.580-1.034)	0.083
Pooled	-0.084	r∎i	0.919 (0.819-1.032)	0.152
Cardiovascular mortality				
UKB	0.003		1.003 (1.001-1.005)	3.64E-03
FinnGen	0.047	⊧	1.048 (0.766-1.435)	0.769
Pooled	0.003		1.003 (1.001-1.005)	3.61E-03
Lipid traits			,	
HDL cholesterol				
UKB	0.020	F	1.020 (0.946-1.099)	0.608
GLGC	0.077		1.080 (0.917-1.271)	0.357
Pooled	0.030		1 030 (0.962-1.103)	0.395
	0.000		1.000 (0.002 - 1.100)	0.000
	0.028		0.062 (0.956 1.002)	0.524
UND	-0.050		1.04E (0.030-1.063)	0.524
ULUL De ala d	0.044		1.045 (0.872-1.253)	0.035
Poolea	-0.014		0.987 (0.894-1.089)	0.788
ingiycerides	0.007	_	0.007 (0.000 4.45 *	0.482
UKB	-0.097		0.907 (0.690-1.194)	0.488
GLGC	-0.256		0.774 (0.580-1.034)	0.083
Pooled	-0.172		0.842 (0.690-1.027)	0.090
Apolipoprotein A				
UKB	-0.016		0.984 (0.976-0.993)	0.470
Apolipoprotein B				
UKB	-0.005	H H H	0.995 (0.955-1.036)	0.799
Lipoprotein A				
UKB	-0.018	HER	0.982 (0.939-1.027)	0.423
			. ,	

FIGURE 4 | The association between fasting glucose (mmol/mol) and outcomes.

Complementary Analyses

MVMR was conducted for outcomes with significant estimates in primary analyses. Most results of univariable MR were supported by MVMR. However, the causal effects of T2DM on HF, FI on IHD, FG on PAD, FG on CA, and HbA_{1c} on CA were not found following adjustment for the other three exposures. An inverse association between T2DM and level of LDL-C was observed using multivariable analysis. Detailed results of MVMR were presented in **Supplementary Table 11**.

DISCUSSION

In this study, a two-sample MR method utilizing GWAS summary-level data was applied to explore the causal association of T2DM and glycemic traits (FG, FI, and HbA_{1c}) with a wide range of CVDs as well as lipid traits [HDL-C, LDL-C, triglycerides, apoA, apoB, and Lp(a)]. The primary analyses found evidence that genetically predicted T2DM was associated with various types of CVDs including MI, HF, IHD, CA,

6

Outcomes	Beta	Forrest Plot/ Odd Ratios (95% CI)	P value
Diseases			
Myocardial infarction			
CARDIoGRAMplusC4D	0.596	1.815 (1.068-3.085)	0.028
FinnGen	0.873	2.393 (1.192-4.805)	0.014
Pooled	0.698	2 009 (1 317-3 064)	1 20E-03
Heart feilure	0.030	- 2.003 (1.517-5.004)	1.202-00
Heart failure	0.170		0.004
HERMES	0.179	1.196 (0.800-1.788)	0.384
FinnGen	0.665	1.945 (1.170-3.234)	0.010
Pooled	0.366	1.442 (1.052-1.978)	0.023
Ischemic heart disease			
CARDIoGRAMplusC4D	0.721	2 057 (1 278-3 311)	2 98E-03
EinnGon	0.660		0.046
FilliGen	0.009		0.046
Pooled	0.703	2.020 (1.374-2.972)	3.53E-04
Coronary atherosclerosis			
UKB	0.032	1.033 (1.004-1.062)	0.024
FinnGen	0.745	2.106 (1.097-4.040)	0.025
Pooled	0.034	1.034 (1.006-1.064)	0.019
Peripheral artery disease			
BB1	1 285	3.61/ (1.510.9.650)	3 91F-03
Fine Can	0.955	0.014 (1.010-0.000)	0.021
FiniGen	0.000		0.021
Pooled	1.031	2.804 (1.604-4.902)	2.97E-04
Essential hypertension			
UKB	0.089	1.093 (1.050-1.138)	1.55E-05
FinnGen	0.969	▶ 2.634 (1.471-4.719)	1.13E-03
Pooled	0.093	1.098 (1.054-1.144)	8.31E-06
Major coronary heart disease event			
LIKR	0.021	1 021 (1 001 1 041)	0.039
FineCon	0.521		0.000
FinitGen	0.001	1.076 (0.849-3.309)	0.137
Pooled	0.021	1.021 (1.001-1.042)	0.036
Stroke			
MEGASTROKE	0.196	1.216 (0.841-1.759)	0.298
FinnGen	0.617	1.853 (1.144-3.004)	0.012
Pooled	0.351	1.421 (1.060-1.905)	0.019
Ischemic stroke			
MECASTROKE	0.1.47	1 150 (0 902 1 670)	0.421
MEGASTRORE	0.147	1.136 (0.603-1.076)	0.451
FinnGen	0.777	2.175 (1.374-3.441)	9.09E-04
Pooled	0.392	1.480 (1.111-1.970)	0.007
Intracranial haemorrhage			
UKB	-1.55E-03	• 0.998 (0.993-1.004)	0.597
FinnGen	0.354	1.425 (0.616-3.300)	0.408
Pooled	-1 53E-03	0.998 (0.993-1.004)	0.601
Atrial fibrillation and fluttering	-1.000-00	- 0.000 (0.000-1.004)	0.001
Atrial librillation and liuttering	0.071		0.701
Multi-cohorts	-0.071	0.931 (0.648-1.339)	0.701
FinnGen	0.661	I.937 (1.062-3.531)	0.031
Pooled	0.125	1.133 (0.830-1.545)	0.432
Cardiovascular mortality			
UKB	0.004	1.004 (0.998-1.009)	0.216
FinnGen	0.359	1 432 (0 806-2 546)	0.221
Pooled	0.004		0.212
Linid traits	0.004	T.004 (0.990-1.009)	0.212
HUL cholesterol			
UKB	-0.351	H■H 0.704 (0.593-0.837)	6.73E-05
GLGC	-0.976		6.02E-06
Pooled	-0.440	0.644 (0.549-0.755)	6.56E-08
LDL cholesterol			
UKB	-0.204	0.816 (0.592-1.124)	0.213
GLCC	-0172	0.942 (0.542 1.205)	0.4.41
Declard	-0.172	0.042 (0.043-1.305)	0.441
Pooled	-0.183	0.825 (0.636-1.068)	U.144
Iriglycerides		_	
UKB	0.283	1.328 (0.535-3.294)	0.541
GLGC	0.271	1.311 (0.519-3.308)	0.566
Pooled	0.277	1.319 (0.690-2.524)	0.402
Apolipoprotein A			
LIKR	-0.236	0.790 (0.713-0.874)	5.37E-06
Analinaprotain P	0.200	- 0.130 (0.113-0.014)	5.012-00
	0.005		0.055
UKB	-0.025	0.975 (0.874-1.088)	0.055
Lipoprotein A			
UKB	-0.135	■ 0.873 (0.780-0.978)	0.019

FIGURE 5 | The association between fasting insulin (mmol/mol) and outcomes.

MCHDE, PAD, HT, stroke, IS, and CM. Additionally, T2DM was associated with a higher level of triglycerides but lower levels of HDL-C and apoA. Moreover, causal effect of glycemic traits on CVDs and lipid traits were also observed. FI was associated with higher levels of HDL-C and triglycerides, and HbA_{1c} was associated with a higher level of LDL-C. Sensitivity analyses suggested the robustness of the causal effects. As a

complementary analysis, MVMR was conducted which incorporated the four exposures into a model. Most results of univariable MR were supported by multivariable MR.

T2DM and CVDs

Our findings are in line with the previous MR studies supporting casual effects of T2DM on various CVDs (14). We here provide

	Outcomes	Beta	Forrest Plot/ Odd Ratios	(95% CI)	P value
	Diseases				
Myocardia	al infarction				
C	ARDIoGRAMplusC4D	0.222		1.249 (1.007-1.550)	0.043
	FinnGen	0.084		1.087 (0.677-1.746)	0.729
	Pooled	0.199		1.220 (1.002-1.484)	0.047
Heart fail	ure				
	HERMES	-0.120		0.887 (0.667-1.179)	0.408
	FinnGen	-0.208		0.812 (0.540-1.222)	0.319
	Pooled	-0.149	► -	0.862 (0.682-1.089)	0.213
Ischemic h	neart disease				
C.	ARDIoGRAMplusC4D	0.283	·₽	1.327 (1.094-1.611)	0.004
	FinnGen	0.102	· · · · ·	1.108 (0.764-1.605)	0.590
	Pooled	0.244	H	1.277 (1.075-1.516)	0.005
Coronary	atherosclerosis				
	UKB	0.019	-	1.019 (1.008-1.031)	6.69E-04
	FinnGen	0.054	F	1.055 (0.670-1.662)	0.817
	Pooled	0.019	-	1.019 (1.008-1.031)	6.58E-04
Periphera	l artery disease				
	BBJ	0.200	∎ →	1.222 (0.508-2.937)	0.654
	FinnGen	0.148	⊢ ∎ →	1.160 (0.657-2.048)	0.610
	Pooled	0.164	⊢ – →	1.178 (0.731-1.897)	0.502
Essential I	hypertension			,	
	UKB	0.002	+	1.002 (0.966-1.038)	0.929
	FinnGen	-0.194		0.824 (0.507-1.339)	0.435
	Pooled	0.001	+	1.001 (0.965-1.037)	0.975
Major cor	onary heart disease even	t		2.002 (0.000 2.001)	0.010
	LIKR	-0.007	•	0.993 (0.981-1.005)	0.255
	FinnGen	0.116	F	1 123 (0 741-1 702)	0.200
	Pooled	-0.007		0.993 (0.991 1.005)	0.000
Stroke	rooleu	-0.007	T	0.333 (0.301-1.003)	0.202
JUOKE	MEGASTROVE	0.149		0.863 (0.620 1.105)	0.262
	FinnGen	-0.140		0.862 (0.655 1.226)	0.302
	FINIGEN	-0.149		0.002 (0.003-1.330)	0.500
la de consta a	Pooled	-0.148		0.862 (0.667-1.115)	0.259
ischemic s	troke	0.404		0.051 (0.500, 4.000)	0.004
	MEGASTROKE	-0.161		0.851 (0.593-1.223)	0.384
	FinnGen	-0.231		0.794 (0.517-1.218)	0.290
	Pooled	-0.190		0.827 (0.627-1.091)	0.179
Intracrani	al haemorrhage				
	UKB	-1.03E-03	_	0.999 (0.996-1.002)	0.464
	FinnGen	-0.299		0.742 (0.405-1.358)	0.332
	Pooled	-1.04E-03	-	0.999 (0.996-1.002)	0.461
Atrial fibr	illation and fluttering				
	Multi-cohorts	-0.064	⊢_≣ 1	0.938 (0.781-1.126)	0.490
	FinnGen	-0.337		0.714 (0.415-1.230)	0.224
	Pooled	-0.092	⊫∎∔∹	0.912 (0.767-1.085)	0.298
Cardiovas	cular mortality				
	UKB	0.002	•	1.002 (0.999-1.006)	0.124
	FinnGen	-0.232		0.793 (0.527-1.192)	0.264
	Pooled	0.002	•	1.002 (0.999-1.006)	0.127
	Lipid traits				
HDL chole	sterol				
	UKB	0.005	H	1.005 (0.941-1.072)	0.885
	GLGC	0.059	⊢	1.061 (0.880-1.280)	0.534
	Pooled	0.011	H	1.011 (0.951-1.075)	0.729
LDL chole	sterol				
	UKB	0.186	HEH	1.205 (1.157-1.255)	4.24E-19
	GLGC	0.234	F	1.264 (0.928-1.721)	0.137
	Pooled	0.187	H E H	1.205 (1 157-1 256)	2.81F-19
Triglycerie	les			(
	UKB	0.070	F	1.073 (0 932-1 235)	0.329
	GLGC	-0.034		0.966 (0.834-1.119)	0.646
	Pooled	0.020		1 020 (0 922-1 120)	0.698
Anolinen	rotein A	0.020		1.020 (0.322-1.130)	0.030
whoubobi	LIKR	-0.012		0.087 (0.044 1.022)	0 572
Analia		-0.013	· · · · · · · · · · · · · · · · · · ·	0.967 (0.944-1.032)	0.573
Apolipopi	OLEIN B	0.055	-	4.050 (4.014.4.45.	0.045
	UKB	0.055	1	1.056 (1.011-1.104)	0.015
Lipoprote	in A				
	UKB	6.53E-04	H H H	1.001 (0.944-1.061)	0.983
		0.400 0	000 0.800 1.000 1.200 1.400 1.600 1.800		

evidence supporting additional effects of T2DM on HT, CA, and CM. However, in our MR study, the causal association between T2DM and HF disappeared after adjusting for multiple variables, which was inconsistent with the results of Liu et al. Moreover, multiple epidemiological studies had consistent results with ours (36–38). However, Wei et al. investigated the association

between T2DM and several CVDs using phenotype and genetic predisposition data from the China Kadoorie Biobank. At the observational level, a significantly positive correlation was observed for all CVD outcomes but not for major coronary events, cardiovascular mortality, or total stroke at the genetic level (39). This discrepancy between observational and genetic results suggests that the causal link between T2DM and CVDs remains largely to be determined. Fortunately, we found the causal effect of T2DM on these diseases.

Unfortunately, we failed to obtain a causal effect of T2DM on AF and IH. No association of T2DM with AF was also found by Hadi et al. using the MR approach (40). However, the Framingham Heart Study observed a 1.4- to 1.6-fold greater risk of AF in diabetic individuals after adjusting for age and other risk factors (41). One hypothesis about this inconsistency was that hypertension and obesity are the common comorbidities of T2DM, which could result in confounder bias in the observational studies, but not in the MR studies (40). In another MR study focusing on T2DM and cerebral disease, the researcher also found the null association between T2DM and IH even subdividing IH into lobar IH and deep IH (42).

Glycemic Traits and CVDs

Previous MR results showed that HbA_{1c} has a causal role in coronary artery disease but FG does not (43). However, in our study, FG was also shown to have a causal effect on several types of coronary artery diseases. Notably, with regard to glycemic traits, some epidemiological evidence did not support our findings of their causal effects on CVDs. The results derived from the Jackson Heart Study (JHS) revealed that dysglycemia, including higher levels of FG and HbA_{1c}, was associated with an increased risk of HF (44), which failed to reappear in our MR study. We inferred that ethnic variation may have led to the difference in results since the JHS recruited mainly Black participants from Mississippi. Justin et al. found that even stratifying the HF into HF with preserved ejection fraction and reduced ejection fraction, the causal chain was still there (45).

T2DM-Related Traits and Lipid Traits

As suggested by our data, T2DM negatively affected HDL-C. Accordingly, a causal effect of T2DM on the decreased level of apoA (a main component of HDL-C) was also observed. Decreased HDL-C levels in T2DM patients was observed in a previous observational study (46). One explanation was that insulin resistance in T2DM patients might be responsible for the low level of HDL-C (47). As far as we know, our study is the first to provide evidence on the causal association between T2DM and a lower level of HDL-C from the genetic level. In our study, T2DM was also found to be causally associated with triglycerides, which is consistent with a previous MR study (48).

In our study, HbA_{1c} was causally associated with an increased level of LDL-C. A transversal observational study found that oxidized LDL-C, rather than total LDL-C, was associated with HbA_{1c} in the non-diabetic range (49). However, we could not obtain data to stratify LDL-C into subgroups to explore this relation further. In our study, FI was found to negatively affected on Lp(a), and it showed a potentially negative effect. Conversely, Buchmann et al. found no evidence of a causal effect of FI on Lp (a) using rs780094 and rs10195252 (SNPs associated with FI) as IVs through the MR method (50). The possible mechanism by which insulin modulates Lp(a) synthesis may be that increased insulin levels promote the progression of insulin resistance and, under these circumstances, reduce the synthesis of Lp(a) (51).

This study had several strengths. As we known, our study is the first to demonstrate a causal association of T2DM and the related glycemic traits with a broad spectrum of CVDs and dyslipidaemia using MR and employing large GWASs data. Two-sample MR method was utilized, which eliminated residual confounding as much as possible. For the outcomes of CVDs, we utilized two highly representative and independent cohorts to stabilize the results of our causal inference. Moreover, the F-statistics of the genetic variants were mostly more than 10, which indicated that the genetic variants were strong enough to be IVs for exposure. Since T2DM and glycemic traits may interact mutually from the pathogenesis of diseases, multivariable MR was applied to adjust the estimate for these exposures. Ultimately, in order to evaluate the robustness of MR results, different MR methods and tests of heterogeneity and pleiotropy were conducted as additional means of sensitivity analyses.

Some limitations could not be ignored. First, most participants included in the GWASs were of European ancestry. Consequently, whether our findings are generalizable to other populations and regions remains to be determined. Second, it is scarcely possible to remove all pleiotropy in MR studies, and some undetected pathways may play a role as confounders between exposures and outcomes, biasing our results. Third, we could obtain only summary-level GWAS data, failing to conduct further investigation on the sex-, age-, and specific type of exposurerelated effect on the outcomes. Moreover, the results of MVMR were possibly biased by overfitting from the multivariable model and attenuated or amplified the estimates of effect, which was also observed in this study as compared to the univariable MR. Last, since the glycemic and lipid traits were predisposed as continuous variables, we assumed that the relationship between T2DM or CVDs was linear, which could be inconsistent with the actual situation.

In conclusion, our MR study provides further evidence that T2DM and its related glycemic traits play a causal role in the increased risk of various CVDs and dyslipidemia. The findings should be interpreted to strengthen the awareness of early detection of T2DM and its related glycemic traits. Further work using individual-level data or basic science approaches to investigate the mechanisms mediating these causal associations is warranted.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

MH and LL designed the study. MH, LZ, and LL undertook the data analyses with feedback from TT and XC. MH and LL cowrote the paper. TT and XC reviewed and provided important suggestions for the manuscript. TT and XC are the guarantors of this study. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Grants from the National Natural Science Foundation of China (81720108005 and 82030016 to XC; 81974037 and 82170394 to TT), the Foundation for Innovative Research Groups of National

REFERENCES

- Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, et al. The Effects of Diabetes on the Risks of Major Cardiovascular Diseases and Death in the Asia-Pacific Region. *Diabetes Care* (2003) 26(2):360–6. doi: 10.2337/ diacare.26.2.360
- Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q. Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-H Plasma Glucose Levels Within a Normoglycemic Range. *Diabetes Care* (2010) 33(10):2211–6. doi: 10.2337/dc09-2328
- Libman IM, Barinas-Mitchell E, Bartucci A, Chaves-Gnecco D, Robertson R, Arslanian S. Fasting and 2-Hour Plasma Glucose and Insulin: Relationship With Risk Factors for Cardiovascular Disease in Overweight Nondiabetic Children. *Diabetes Care* (2010) 33(12):2674–6. doi: 10.2337/dc10-0085
- Gore MO, McGuire DK. A Test in Context: Hemoglobin A(1c) and Cardiovascular Disease. J Am Coll Cardiol (2016) 68(22):2479–86. doi: 10.1016/j.jacc.2016.08.070
- Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al. Impaired Fasting Glucose and Risk of Cardiovascular Disease in Korean Men and Women: The Korean Heart Study. *Diabetes Care* (2013) 36(2):328–35. doi: 10.2337/dc12-0587
- Preiss D, Welsh P, Murray HM, Shepherd J, Packard C, Macfarlane P, et al. Fasting Plasma Glucose in Non-Diabetic Participants and the Risk for Incident Cardiovascular Events, Diabetes, and Mortality: Results From WOSCOPS 15-Year Follow-Up. *Eur Heart J* (2010) 31(10):1230–6. doi: 10.1093/eurheartj/ehq095
- Cai X, Liu X, Sun L, He Y, Zheng S, Zhang Y, et al. Prediabetes and the Risk of Heart Failure: A Meta-Analysis. *Diabetes Obes Metab* (2021) 23(8):1746–53. doi: 10.1111/dom.14388
- Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association Between Prediabetes and Risk of All Cause Mortality and Cardiovascular Disease: Updated Meta-Analysis. *Bmj* (2020) 370:m2297. doi: 10.1136/bmj.m2297
- Mai L, Wen W, Qiu M, Liu X, Sun L, Zheng H, et al. Association Between Prediabetes and Adverse Outcomes in Heart Failure. *Diabetes Obes Metab* (2021) 23(11):2476–83. doi: 10.1111/dom.14490
- Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. *Lancet* (2010) 375(9733):2215–22. doi: 10.1016/s0140-6736(10)60484-9
- Welsh C, Welsh P, Celis-Morales CA, Mark PB, Mackay D, Ghouri N, et al. Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. *Diabetes Care* (2020) 43(2):440–5. doi: 10.2337/ dc19-1683
- Mancini GBJ, Hegele RA, Leiter LA. Dyslipidemia. Can J Diabetes (2018) 42 Suppl 1:S178–s85. doi: 10.1016/j.jcjd.2017.10.019
- Benn M, Nordestgaard BG. From Genome-Wide Association Studies to Mendelian Randomization: Novel Opportunities for Understanding Cardiovascular Disease Causality, Pathogenesis, Prevention, and Treatment. *Cardiovasc Res* (2018) 114(9):1192–208. doi: 10.1093/cvr/cvy045
- Liu B, Mason AM, Sun L, Di Angelantonio E, Gill D, Burgess S. Genetically Predicted Type 2 Diabetes Mellitus Liability, Glycated Hemoglobin and Cardiovascular Diseases: A Wide-Angled Mendelian Randomization Study. *Genes (Basel)* (2021) 12(10):1644. doi: 10.3390/genes12101644

Natural Science Foundation of China (82021005 to XC), and the 2017 Chang Jiang Scholars Program (T2017073 to XC).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022. 840579/full#supplementary-material

- Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base Platform Supports Systematic Causal Inference Across the Human Phenome. *Elife* (2018) 7:e34408. doi: 10.7554/eLife.34408
- Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. *bioRxiv* (2020). doi: 10.1101/ 2020.08.10.244293
- Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-Mapping Type 2 Diabetes Loci to Single-Variant Resolution Using High-Density Imputation and Islet-Specific Epigenome Maps. *Nat Genet* (2018) 50(11):1505–13. doi: 10.1038/s41588-018-0241-6
- Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-Scale Association Analyses Identify New Loci Influencing Glycemic Traits and Provide Insight Into the Underlying Biological Pathways. *Nat Genet* (2012) 44 (9):991–1005. doi: 10.1038/ng.2385
- Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, et al. Impact of Common Genetic Determinants of Hemoglobin A1c on Type 2 Diabetes Risk and Diagnosis in Ancestrally Diverse Populations: A Transethnic Genome-Wide Meta-Analysis. *PloS Med* (2017) 14(9): e1002383. doi: 10.1371/journal.pmed.1002383
- Burgess S, Thompson SG. Avoiding Bias From Weak Instruments in Mendelian Randomization Studies. *Int J Epidemiol* (2011) 40(3):755–64. doi: 10.1093/ije/dyr036
- Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of Lifetime Cannabis Use Reveals New Risk Loci, Genetic Overlap With Psychiatric Traits, and a Causal Influence of Schizophrenia. *Nat Neurosci* (2018) 21(9):1161–70. doi: 10.1038/s41593-018-0206-1
- Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian Randomization: Using Genes as Instruments for Making Causal Inferences in Epidemiology. *Stat Med* (2008) 27(8):1133–63. doi: 10.1002/sim.3034
- Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A Comprehensive 1,000 Genomes-Based Genome-Wide Association Meta-Analysis of Coronary Artery Disease. *Nat Genet* (2015) 47(10):1121–30. doi: 10.1038/ng.3396
- 24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PloS Med* (2015) 12(3): e1001779. doi: 10.1371/journal.pmed.1001779
- Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry Genome-Wide Association Study of 520,000 Subjects Identifies 32 Loci Associated With Stroke and Stroke Subtypes. *Nat Genet* (2018) 50 (4):524–37. doi: 10.1038/s41588-018-0058-3
- 26. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. Genome-Wide Association and Mendelian Randomisation Analysis Provide Insights Into the Pathogenesis of Heart Failure. *Nat Commun* (2020) 11 (1):163. doi: 10.1038/s41467-019-13690-5
- Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A Cross-Population Atlas of Genetic Associations for 220 Human Phenotypes. *Nat Genet* (2021) 53(10):1415–24. doi: 10.1038/s41588-021-00931-x
- Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-Driven Genomic Discovery Yields New Insight Into Atrial Fibrillation Biology. *Nat Genet* (2018) 50(9):1234–9. doi: 10.1038/s41588-018-0171-3

- Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and Refinement of Loci Associated With Lipid Levels. *Nat Genet* (2013) 45(11):1274–83. doi: 10.1038/ng.2797
- Burgess S, Thompson SG. Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation. New York:CRC Press (2015).
- Burgess S, Thompson SG. Interpreting Findings From Mendelian Randomization Using the MR-Egger Method. Eur J Epidemiol (2017) 32 (5):377-89. doi: 10.1007/s10654-017-0255-x
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring Inconsistency in Meta-Analyses. Bmj (2003) 327(7414):557–60. doi: 10.1136/bmj.327.7414.557
- 33. Verbanck M, Chen CY, Neale B, Do R. Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred From Mendelian Randomization Between Complex Traits and Diseases. *Nat Genet* (2018) 50(5):693–8. doi: 10.1038/s41588-018-0099-7
- Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization With Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* (2016) 40(4):304–14. doi: 10.1002/ gepi.21965
- 35. Gao Y, Mi J, Liu Z, Song Q. Leisure Sedentary Behavior and Risk of Lung Cancer: A Two-Sample Mendelian Randomization Study and Mediation Analysis. *Front Genet* (2021) 12:763626. doi: 10.3389/fgene.2021.763626
- 36. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality From Coronary Heart Disease in Subjects With Type 2 Diabetes and in Nondiabetic Subjects With and Without Prior Myocardial Infarction. N Engl J Med (1998) 339(4):229–34. doi: 10.1056/nejm199807233390404
- Himmelmann A, Hansson L, Svensson A, Harmsen P, Holmgren C, Svanborg A. Predictors of Stroke in the Elderly. *Acta Med Scand* (1988) 224(5):439–. doi: 10.1111/j.0954-6820.1988.tb19608.x
- Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Non-Insulin-Dependent Diabetes and its Metabolic Control are Important Predictors of Stroke in Elderly Subjects. *Stroke* (1994) 25(6):1157–64. doi: 10.1161/01.str.25.6.1157
- Gan W, Bragg F, Walters RG, Millwood IY, Lin K, Chen Y, et al. Genetic Predisposition to Type 2 Diabetes and Risk of Subclinical Atherosclerosis and Cardiovascular Diseases Among 160,000 Chinese Adults. *Diabetes* (2019) 68 (11):2155–64. doi: 10.2337/db19-0224
- Harati H, Zanetti D, Rao A, Gustafsson S, Perez M, Ingelsson E, et al. No Evidence of a Causal Association of Type 2 Diabetes and Glucose Metabolism With Atrial Fibrillation. *Diabetologia* (2019) 62(5):800–4. doi: 10.1007/ s00125-019-4836-y
- Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort. The Framingham Heart Study. JAMA (1994) 271(11):840–4. doi: 10.1001/ jama.271.11.840
- Liu J, Rutten-Jacobs L, Liu M, Markus HS, Traylor M. Causal Impact of Type 2 Diabetes Mellitus on Cerebral Small Vessel Disease: A Mendelian Randomization Analysis. *Stroke* (2018) 49(6):1325–31. doi: 10.1161/ strokeaha.117.020536
- 43. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Mendelian Randomization Analysis Supports the Causal Role of Dysglycaemia and

Diabetes in the Risk of Coronary Artery Disease. *Eur Heart J* (2015) 36 (23):1454–62. doi: 10.1093/eurheartj/ehv083

- 44. Echouffo-Tcheugui JB, Mwasongwe SE, Musani SK, Hall ME, Correa A, Hernandez AF, et al. Dysglycemia and Incident Heart Failure Among Blacks: The Jackson Heart Study. Am Heart J (2021), 245:1–9. doi: 10.1016/ j.ahj.2021.11.003
- 45. Echouffo-Tcheugui JB, Ogunmoroti O, Golden SH, Bertoni AG, Mongraw-Chaffin M, Pandey A, et al. Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA). *J Card Fail* (2022). doi: 10.1016/j.cardfail.2022.01.011
- 46. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, et al. Poor Glycemic Control is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes. *Diabetes Care* (2009) 32(8):1550–2. doi: 10.2337/dc09-0256
- Srivastava RAK. Dysfunctional HDL in Diabetes Mellitus and its Role in the Pathogenesis of Cardiovascular Disease. *Mol Cell Biochem* (2018) 440(1-2):167–87. doi: 10.1007/s11010-017-3165-z
- Wang N, Cheng J, Ning Z, Chen Y, Han B, Li Q, et al. Type 2 Diabetes and Adiposity Induce Different Lipid Profile Disorders: A Mendelian Randomization Analysis. J Clin Endocrinol Metab (2018) 103(5):2016–25. doi: 10.1210/jc.2017-02789
- Spessatto D, Brum L, Camargo JL. Oxidized LDL But Not Total LDL is Associated With HbA1c in Individuals Without Diabetes. *Clin Chim Acta* (2017) 471:171–6. doi: 10.1016/j.cca.2017.06.004
- Buchmann N, Scholz M, Lill CM, Burkhardt R, Eckardt R, Norman K, et al. Association Between Lipoprotein(a) Level and Type 2 Diabetes: No Evidence for a Causal Role of Lipoprotein(a) and Insulin. *Acta Diabetol* (2017) 54 (11):1031–8. doi: 10.1007/s00592-017-1036-4
- Neele DM, de Wit EC, Princen HM. Insulin Suppresses Apolipoprotein(a) Synthesis by Primary Cultures of Cynomolgus Monkey Hepatocytes. *Diabetologia* (1999) 42(1):41–4. doi: 10.1007/s001250051110

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Huang, Laina-Nicaise, Zha, Tang and Cheng. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.